[go: up one dir, main page]

FI922345L - Menetelmä terapeuttisesti käyttökelpoisten 3-substituoitujen pyrrolidiinijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 3-substituoitujen pyrrolidiinijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI922345L
FI922345L FI922345A FI922345A FI922345L FI 922345 L FI922345 L FI 922345L FI 922345 A FI922345 A FI 922345A FI 922345 A FI922345 A FI 922345A FI 922345 L FI922345 L FI 922345L
Authority
FI
Finland
Prior art keywords
therapeutically useful
pyrrolidine derivatives
substituted pyrrolidine
preparing therapeutically
preparing
Prior art date
Application number
FI922345A
Other languages
English (en)
Swedish (sv)
Other versions
FI95027B (fi
FI922345A0 (fi
FI95027C (fi
Inventor
Alexander Roderick Mackenzie
Peter Edward Cross
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI922345L publication Critical patent/FI922345L/fi
Publication of FI922345A0 publication Critical patent/FI922345A0/fi
Publication of FI95027B publication Critical patent/FI95027B/fi
Application granted granted Critical
Publication of FI95027C publication Critical patent/FI95027C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI922345A 1989-12-12 1992-05-22 Menetelmä terapeuttisesti käyttökelpoisten 3-substituoitujen pyrrolidiinijohdannaisten valmistamiseksi FI95027C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898928042A GB8928042D0 (en) 1989-12-12 1989-12-12 Muscarinic receptor antagonists
GB8928042 1989-12-12
PCT/EP1990/002043 WO1991009013A1 (en) 1989-12-12 1990-11-28 Muscarinic receptor antagonists
EP9002043 1990-11-28

Publications (4)

Publication Number Publication Date
FI922345L true FI922345L (fi) 1992-05-22
FI922345A0 FI922345A0 (fi) 1992-05-22
FI95027B FI95027B (fi) 1995-08-31
FI95027C FI95027C (fi) 1995-12-11

Family

ID=10667813

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922345A FI95027C (fi) 1989-12-12 1992-05-22 Menetelmä terapeuttisesti käyttökelpoisten 3-substituoitujen pyrrolidiinijohdannaisten valmistamiseksi

Country Status (14)

Country Link
US (1) US5340831A (fi)
EP (1) EP0505376B1 (fi)
JP (1) JPH0678303B2 (fi)
AT (1) ATE115126T1 (fi)
CA (1) CA2069910C (fi)
DE (1) DE69014901T2 (fi)
DK (1) DK0505376T3 (fi)
ES (1) ES2064771T3 (fi)
FI (1) FI95027C (fi)
GB (1) GB8928042D0 (fi)
GR (1) GR3014907T3 (fi)
IE (1) IE64205B1 (fi)
PT (1) PT96144A (fi)
WO (1) WO1991009013A1 (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569664A (en) * 1995-02-16 1996-10-29 Fmc Corporation Insecticidal n-(substituted arylmethyl)-4-[bis(substituted phenyl) methyl]pi
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
JP4167302B2 (ja) * 1996-12-02 2008-10-15 杏林製薬株式会社 新規ｎ―置換ピロリジン誘導体及びその製造法
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
MXPA05000434A (es) 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
HK1079787A1 (zh) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物
WO2004014363A1 (en) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
WO2004052857A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100406009C (zh) 2003-04-10 2008-07-30 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物
EP1626957A1 (en) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US7368463B2 (en) 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
WO2005087722A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
JP2007528418A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
EP1926709A4 (en) 2005-08-25 2009-06-24 Rstech Corp PROCESS FOR THE SYNTHESIS OF A 3-HYDROXYPYRROLIDINE CHIRAL COMPOUND AND DERIVATIVES OF SAID HIGH OPTICAL PURITY COMPOUND
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CA2630478A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries, Ltd Processes for preparing darifenacin hydrobromide
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
EP2146957B1 (en) 2007-04-24 2013-06-12 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
WO2010058429A1 (en) 2008-11-24 2010-05-27 Council Of Scientific & Industrial Research A process for the preparation of optically active n-benzyl-3 hydroxypyrrolidines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
US4810713A (en) * 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
EP0235463A3 (en) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
IN163948B (fi) * 1986-01-17 1988-12-10 Robins Co Inc A H
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
JPH0678303B2 (ja) 1994-10-05
DK0505376T3 (da) 1995-02-13
IE904463A1 (en) 1991-06-19
EP0505376B1 (en) 1994-12-07
ES2064771T3 (es) 1995-02-01
WO1991009013A1 (en) 1991-06-27
CA2069910A1 (en) 1991-06-13
ATE115126T1 (de) 1994-12-15
DE69014901D1 (de) 1995-01-19
GR3014907T3 (en) 1995-05-31
DE69014901T2 (de) 1995-04-27
JPH04505927A (ja) 1992-10-15
PT96144A (pt) 1991-09-30
EP0505376A1 (en) 1992-09-30
FI95027B (fi) 1995-08-31
IE64205B1 (en) 1995-07-12
FI922345A0 (fi) 1992-05-22
CA2069910C (en) 1996-11-12
GB8928042D0 (en) 1990-02-14
FI95027C (fi) 1995-12-11
US5340831A (en) 1994-08-23

Similar Documents

Publication Publication Date Title
FI922345L (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-substituoitujen pyrrolidiinijohdannaisten valmistamiseksi
FI905941A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten 2-asyyliaminotiatsolijohdannaisten valmistamiseksi
FI893433A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
FI890282L (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI885409A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridatsiiniamiinijohdannaisten valmistamiseksi
FI883744L (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia indolijohdoksia
FI881180L (fi) Menetelmä terapeuttisesti käytettävien tetrahydronaftaleenijohdannaisten valmistamiseksi
FI883064A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
FI894217L (fi) 1-adamantaanijohdannaisten valmistusmenetelmä
FI892182A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI893361L (fi) Menetelmä ACAT-inhiboivien kinoliinijohdannaisten valmistamiseksi
FI940769L (fi) Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi
FI884627A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten dideoksisytidiinijohdannaisten valmistamiseksi
FI930150L (fi) Menetelmä terapeuttisesti aktiivisten indolijohdannaisten valmistamiseksi
FI894803L (fi) Menetelmä terapeuttisesti käyttökelpoisten kinolinonijohdannaisten valmistamiseksi
FI893701L (fi) Menetelmä antipsykoottisten 3-piperatsinyylibentsatsolijohdannaisten valmistamiseksi
FI883672A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
FI884910A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsopyraanijohdannaisten valmistamiseksi
FI892948A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI881525A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten N-aryylipiperatsiiniasetamidijohdannaisten valmistamiseksi
FI924642L (fi) Menetelmä terapeuttisesti aktiivisten 3-indolyylitioasetaattijohdannaisten valmistamiseksi
FI893003L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
FI890257A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi
FI885560A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
FI880716A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten aryylipiperatsinyylialkyleenifenyylisubstituoitujen heterosyklisten yhdisteiden valmistamiseksi

Legal Events

Date Code Title Description
BB Publication of examined application
MA Patent expired